Abstract |
While the efficacy of daunorubicin (DNR) in first induction of patients with acute nonlymphoblastic leukemia ( ANLL) has been well documented, little data are available concerning the activity of DNR in patients with relapsed and refractory ANLL previously treated with anthracycline. We administered DNR (60 mg/m2/day for 3-5 days) in 21 patients with relapsed (n = 12) or refractory (n = 9) ANLL previously treated with anthracycline. The general response rate was 48%, with a complete response (CR) rate of 38%. Five of 12 patients with relapsed ANLL and 3 of 9 patients with refractory ANLL achieved CR. Among these cases with CR in refractory ANLL, the evolution of one patient is particularly illustrative since he had received previously a large cumulative dose of anthracycline (540 mg/m2) and has been shown to be refractory to high-dose cytosine arabinoside. This study suggests that previous administration of DNR or adriamycin does not induce significant resistance to anthracycline: DNR appears to be almost as efficient in patients with relapsed and refractory ANLL previously treated with anthracycline as in first induction.
|
Authors | T Velu, L Debusscher, P Stryckmans |
Journal | American journal of hematology
(Am J Hematol)
Vol. 27
Issue 3
Pg. 224-5
(Mar 1988)
ISSN: 0361-8609 [Print] United States |
PMID | 3162347
(Publication Type: Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Naphthacenes
- Doxorubicin
- Daunorubicin
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Aged
- Antibiotics, Antineoplastic
- Daunorubicin
(therapeutic use)
- Doxorubicin
(therapeutic use)
- Female
- Humans
- Leukemia
(drug therapy)
- Male
- Middle Aged
- Naphthacenes
(therapeutic use)
- Neoplasm Recurrence, Local
|